ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer

A developed small lung metastases (ie, millimetres-wide) in April, 2021, after neoadjuvant FOLFIRINOX followed by radical surgery; when the largest lesion reached Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST) measurability (February, 2022), she was enrolled in a poly (ADP-ribose)...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2022-08, Vol.23 (8), p.991-992
Main Authors: Milella, Michele, Lawlor, Rita T, Luchini, Claudio, Johns, Amber L, Casolino, Raffaella, Yoshino, Takayuki, Biankin, Andrew V, Scarpa, Aldo
Format: Article
Language:English
Subjects:
Adenomatous polyposis coli
Humans
Lung cancer
Metastases
Metastasis
MSH6 protein
Mutation
Pancreatic cancer
Pancreatic Neoplasms
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - genetics
Pharmaceuticals
Poly(ADP-ribose) polymerase
Precision Medicine
Ribose
Solid tumors
Thyroid cancer
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A developed small lung metastases (ie, millimetres-wide) in April, 2021, after neoadjuvant FOLFIRINOX followed by radical surgery; when the largest lesion reached Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST) measurability (February, 2022), she was enrolled in a poly (ADP-ribose) polymerase (PARP) inhibitor phase 1 trial (NCT04182516). The relative risk of both cancers is increased in germline carriers of mutations in APC, PALB2, MSH6, and CHEK2. [...]both M and A developed lung-only metastases with a particularly indolent clinical course. TY declares grants from Ono Pharmaceutical, Sanofi, Daiichi Sankyo, PAREXEL International, Pfizer Japan, Taiho Pharmaceutical, MSD, Amgen, Genomedia, Sysmex Corporation, Chugai Pharmaceutical, and Nippon Boehringer Ingelheim; payment or honoraria for lectures, presentations, or other from Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Merck, Bayer Yakuhin, Ono Pharmaceutical, and MSD; and participating on a data safety moniroting or advisory board for Asahi Kasei Pharma America Corporation.
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(22)00448-X